Successful use of intensive immunosuppressive therapy for treating simultaneously occurring cerebral lesions and pulmonary arterial hypertension in a patient with systemic lupus erythematosus

Internal Medicine

Volumn 53, Issue 6, 2014, Pages 627-631

  Watanabe, Ryu ^a   Fujii, Hiroshi ^a   Shirai, Tsuyoshi ^a   Saito, Shinichiro ^a   Hatakeyama, Akira ^b   Sugimura, Koichiro ^a   Fukumoto, Yoshihiro ^a   Ishii, Tomonori ^a   Harigae, Hideo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU ROSAI HOSPITAL   (Japan)

Author keywords

Cerebral lesion; Pulmonary arterial hypertension; Systemic lupus erythematosus

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; PREDNISOLONE; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; ATAXIA; BLOOD PRESSURE; BRAIN DAMAGE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DRUG MEGADOSE; DRUG PULSE THERAPY; DYSARTHRIA; ELECTROENCEPHALOGRAM; FEMALE; HEART CATHETERIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; MIDDLE AGED; NEUROPSYCHIATRIC LUPUS SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PULMONARY HYPERTENSION; SEROLOGY; STEROID PULSE THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY; BRAIN STEM; CEREBELLUM; COMPLICATION; EDEMA; HYPERTENSION, PULMONARY; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATHOLOGY; REMISSION; TREATMENT OUTCOME;

BRAIN STEM; CEREBELLUM; EDEMA; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84896278477     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.53.0514     Document Type: Article

References (22)

1. Liu Z, Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med 18: 871-882, 2012.
2. Castellino G, Govoni M, Giacuzzo S, Trotta F. Optimizing clinical monitoring of central nervous system involvement in SLE. Autoimmun Rev 7: 297-304, 2008.
3. ACR Ad Hoc Committee on Neuropsychiatric lupus nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42: 599-608, 1999.
4. Borchers AT, Aoki CA, Naguwa SM, Keen CL, Shoenfeld Y, Gershwin ME. Neuropsychiatric features of systemic lupus erythematosus. Autoimmun Rev 4: 329-344, 2005.
5. Dhala A. Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol 2012: 854941, 2012.
6. Johnson SR, Granton JT. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev 20: 277-286, 2011.
7. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179: 151-157, 2009.
8. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35: 630-640, 1992.
9. Efthimiou P, Blanco M. Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers. Mod Rheumatol 19: 457-468, 2009.
10. Bertsias GK, Ioannidis JPA, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EU-LAR standing committee for clinical affairs. Ann Rheum Dis 69: 2074-2082, 2010.
11. Appenzeller S, Pike GB, Clarke AE. Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. Clin Rev Allergy Immunol 34: 361-366, 2008.
12. Moritani T, Hiwatashi A, Shrier DA, Wang HZ, Numaguchi Y, Westesson PL. CNS vasculitis and vasculopathy. Efficasy and usefulness of diffusion-weighted echoplanar MR imaging. Clin Imaging 28: 261-270, 2004.
13. Fujieda Y, Kataoka H, Odani T, et al. Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus. Mod Rheumatol 21: 276-281, 2011.
14. Barber CE, Leclerc R, Gladman DD, Urowitz MB, Fortin PR. Posterior reversible encephalopathy syndrome: an emerging disease manifestation in systemic lupus erythematosus. Semin Arthritis Rheum 41: 353-363, 2011.
15. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest 141: 210-221, 2012.
16. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue disease-associated pulmonary arterial hypertension. Chest 130: 182-189, 2006.
17. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus-and mixed connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 58: 521-531, 2008.
18. Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J 75: 2668-2674, 2011.
19. Hardie RJ, Isenberg DA. Tetraplegia as a presenting feature of systemic lupus erythematosus complicated by pulmonary hypertension. Ann Rheum Dis 44: 491-493, 1985.
20. Funauchi M, Shimadzu H, Tamaki C, et al. Survival study by organ disorders in 306 Japanese patients with systemic lupus erythematosus. Rheumatol Int 27: 243-249, 2007.
21. Cefle A, Inanc M, Sayarlioglu M, et al. Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 31: 183-189, 2011.
22. Shirai T, Fujii H, Ono M, et al. A novel autoantibody against fibronectin leucine-rich transmembrane protein 2 expressed on the endothelial cell surface identified by retroviral vector system in systemic lupus erythematosus. Arthritis Res Ther 14: R157, 2012.